Tofacitinib (Xeljanz®) is the first of a unique class of oral kinase inhibitors to be FDA approved for the treatment of rheumatoid arthritis (RA). Tofacitinib is a selective inhibitor of Janus kinase (JAK) enzymes.
Tofacitinib: A novel Janus kinase inhibitor is FDA approved as the first oral biologic treatment for rheumatoid arthritis
January 10, 2013 By
Challenges in Screening for Latent TB in Inflammatory Arthritis
July 30, 2012 By
Screening for latent TB in patients with inflammatory arthritis who will be starting TNFα inhibitors is important to prevent complications of TB-reactivation. However, currently there is no ‘gold standard’ for the diagnosis of latent TB.
Pregnancy Concerns Among Women with Rheumatoid Arthirits and Lupus
July 15, 2012 By
Many autoimmune diseases have a female predominance. Rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are no exception. Both of these diseases can affect young women in their reproductive years, but little is known about the impact of RA and SLE on a woman’s opinion regarding pregnancy or, further, how this translates into family planning.
Don’t Stop Exercising!
April 24, 2012 By
It has been established that patients with rheumatoid arthritis (RA) have decreased muscle and increased fat compared to those without RA.
Vaccinations in RA: Stay Healthy!
July 22, 2011 By
Vaccinations are a critical component of RA clinical management, and their importance in preventing infection cannot be stressed enough. The majority of patients with RA are on immunosuppressive treatment, and a data driven approach to vaccinations in this high-risk population is essential.
